Several students from the ORBIS (Open Research Biopharmaceutical Internship Support ) program are part of the New Jersey Center for Biomaterials. This program is led at Rutgers by the Center for Dermal Research, which is a part of NJCBM. The CDR hosted nine ORBIS Visiting Scientists from Europe from both academia and pharmaceutical companies in 2018 and will have another six scientists in 2019. Before the funding of the proposal ends in 2021 the CDR will have many more visiting professors and pharmaceutical scientists from many locations in the European Union. The P.I. at Rutgers is Dr. Bozena “Bo” Michniak-Kohn, Professor of Pharmaceutics at the Ernest Mario School of Pharmacy and Director of the CDR.
The ORBIS Project is a response to the current scientific, economic and social challenge of increasing the effectiveness and productivity of drug development process, both for innovative and (super)generic drugs. This goal can be achieved by interdisciplinary cooperation between the academics from different fields of pharmaceutical sciences and the employees of R&D sector in commercial enterprises. The core of ORBIS is constituted by international, intersectoral exchange of researchers between academic centers and pharmaceutical companies – the consortium partners.
During the secondments (training periods) planned in the project, young and experienced scientists will cooperate with the hosting institutions on the most relevant and up-to-date issues of drug development process, such as: synthesis and optimization of new active ingredients, pre-formulation studies, development of novel oral, dermal and transdermal dosage forms, as well as their biopharmaceutical evaluation with new analytical methods. The ORBIS Project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 778051.
More information about this program is available here: http://orbisproject.eu